22.01.2015 Views

Division of Medicinal Chemistry Abstracts-235th ACS National ...

Division of Medicinal Chemistry Abstracts-235th ACS National ...

Division of Medicinal Chemistry Abstracts-235th ACS National ...

SHOW MORE
SHOW LESS
  • No tags were found...

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

MEDI 94<br />

Identification and optimization <strong>of</strong> N3, N6-diaryl-1H-pyrazolo[3,4-d]pyrimidine-3,6-<br />

diamines as a novel class <strong>of</strong> ACK1 inhibitors<br />

Xiaolin Hao 1 , David Kopecky 2 , XianYun Jiao 1 , Yi Chen 1 , Jiasheng Fu 1 , Juan Jaen 3 , Holger<br />

Wesche 4 , Josh Xiao 5 , Edward van der Horst 5 , Jinsong Liu 5 , Zhulun Wang 6 , Mario Cardozo 6 , Ji<br />

Ma 7 , Shichang Miao 3 , Liang Tang 7 , and Frank Kayser 1 . (1) <strong>Chemistry</strong> Research and Discovery,<br />

Amgen Inc, 1120 Veterans BLVD, South San Francisco, CA 94080, xhao@amgen.com, (2)<br />

<strong>Chemistry</strong> Research and Discovery, Amgen SF, South San Francisco, CA 94080, (3)<br />

Department <strong>of</strong> <strong>Chemistry</strong> Research and Discovery, ChemoCentryx, Inc, Mountain View, CA<br />

94043, (4) Department <strong>of</strong> Oncology, Amgen Inc, South San Francisco, CA 94080, (5) Amgen<br />

Inc, South San Francisco, CA 94080, (6) Structural Biology, Amgen San Francisco, LLC, South<br />

San Francisco, CA 94080, (7) Department <strong>of</strong> PKDM, Amgen, Inc, South San Francisco, CA<br />

94080<br />

Abstract -ACK1 (activated Cdc42Hs associated kinase 1) is a non-receptor tyrosine kinase,<br />

ubiquitously expressed, with highest expression levels in the brain. It has been shown to be<br />

over-expressed in a number <strong>of</strong> human tumor cell lines. The development <strong>of</strong> a potent and stable<br />

ACK1 inhibitor would allow the role <strong>of</strong> ACK1 in tumor progression to be probed via in vivo<br />

animal tumor models. Based on the structural information obtained from an earlier series <strong>of</strong><br />

ACK1 inhibitors (I), potential new ligands were designed that retained key binding features but<br />

possessed alternative scaffolds. N3, N6-diaryl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamines (II)<br />

were identified as a novel series <strong>of</strong> inhibitors <strong>of</strong> ACK1.<br />

MEDI 95<br />

Signaling protein modulators as therapeutic agents based on tyrphostin dimer like<br />

structure<br />

Zhenghong Peng 1 , Ashutosh Pal 1 , David S Maxwell 2 , William Bornmann 1 , Shimei Wang 2 ,<br />

Nicholas Donato 3 , and Moshe Talpaz 3 . (1) Diagnostic Imaging, University <strong>of</strong> Texas MD<br />

Anderson Cancer Center, 1515 Holcombe, Houston, TX 77030, Fax: 7135630084,<br />

zhenghong.peng@di.mdacc.tmc.edu, (2) Experimental Diagnostic Imaging, University <strong>of</strong> Texas<br />

M. D. Anderson Cancer Center, Houston, TX 77054, (3) Dept. <strong>of</strong> Internal Medicine/<strong>Division</strong> <strong>of</strong><br />

Hematology/Oncology, University <strong>of</strong> Michigan Comprehensive Cancer Center, Ann Arbor, MI 4<br />

A series <strong>of</strong> dimer like tyrphostin compounds have been designed, synthesized and primary<br />

screened against B-cell malignancies [multiple myeloma - MM-1] cell line. The lead compounds<br />

have nanomolar potency against a wide range <strong>of</strong> tumor types and inhibit against known kinase<br />

target. These new classes <strong>of</strong> compunds hold promise as a cancer therapeutic agent.

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!